These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23955246)

  • 1. Overcoming perceptions of financial barriers to rotavirus vaccine introduction in Asia.
    Nelson EA; de Quadros CA; Santosham M; Parashar UD; Steele D
    Hum Vaccin Immunother; 2013 Nov; 9(11):2418-26. PubMed ID: 23955246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strengthening national decision-making on immunization by building capacity for economic evaluation: Implementing ProVac in Europe.
    Blau J; Hoestlandt C; D Clark A; Baxter L; Felix Garcia AG; Mounaud B; Mosina L
    Vaccine; 2015 May; 33 Suppl 1():A34-9. PubMed ID: 25919171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using surveillance and economic data to make informed decisions about rotavirus vaccine introduction.
    Cohen AL; Aliabadi N; Serhan F; Tate JE; Zuber P; Parashar UD
    Vaccine; 2018 Dec; 36(51):7755-7758. PubMed ID: 30131194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of rotavirus vaccination in Argentina.
    Urueña A; Pippo T; Betelu MS; Virgilio F; Hernández L; Giglio N; Gentile Á; Diosque M; Vizzotti C
    Vaccine; 2015 May; 33 Suppl 1():A126-34. PubMed ID: 25919152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rotavirus vaccination in developing countries.
    Babji S; Kang G
    Curr Opin Virol; 2012 Aug; 2(4):443-8. PubMed ID: 22698800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia.
    Loganathan T; Ng CW; Lee WS; Hutubessy RCW; Verguet S; Jit M
    Health Policy Plan; 2018 Mar; 33(2):204-214. PubMed ID: 29228339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.
    Sigei C; Odaga J; Mvundura M; Madrid Y; Clark AD; ;
    Vaccine; 2015 May; 33 Suppl 1():A109-18. PubMed ID: 25919149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementing rotavirus vaccination in Asia.
    Santosham M; Nelson EA; Bresee JS
    Vaccine; 2007 Nov; 25(44):7711-6. PubMed ID: 17881099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.
    Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ
    Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction of rotavirus vaccination in Palestine: An evaluation of the costs, impact, and cost-effectiveness of ROTARIX and ROTAVAC.
    Debellut F; Jaber S; Bouzya Y; Sabbah J; Barham M; Abu-Awwad F; Hjaija D; Ramlawi A; Pecenka C; Clark A; Mvundura M
    PLoS One; 2020; 15(2):e0228506. PubMed ID: 32023295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimated impact of rotavirus vaccine on hospitalizations and deaths from rotavirus diarrhea among children <5 in Asia.
    Burnett E; Tate JE; Kirkwood CD; Nelson EAS; Santosham M; Steele AD; Parashar UD
    Expert Rev Vaccines; 2018 May; 17(5):453-460. PubMed ID: 29463143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global rotavirus vaccine introductions and coverage: 2006 - 2016.
    Abou-Nader AJ; Sauer MA; Steele AD; Tate JE; Atherly D; Parashar UD; Santosham M; Nelson EAS
    Hum Vaccin Immunother; 2018; 14(9):2281-2296. PubMed ID: 29787334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Projected cost-effectiveness of rotavirus vaccination for children in Asia.
    Podewils LJ; Antil L; Hummelman E; Bresee J; Parashar UD; Rheingans R
    J Infect Dis; 2005 Sep; 192 Suppl 1():S133-45. PubMed ID: 16088797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects for rotavirus vaccine introduction in the Philippines: Bridging the available evidence into immunization policy.
    Lopez AL; Raguindin PF; Silva MWT
    Hum Vaccin Immunother; 2019; 15(6):1260-1264. PubMed ID: 30513238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-evaluating the cost and cost-effectiveness of rotavirus vaccination in Bangladesh, Ghana, and Malawi: A comparison of three rotavirus vaccines.
    Pecenka C; Debellut F; Bar-Zeev N; Anwari P; Nonvignon J; Shamsuzzaman M; Clark A
    Vaccine; 2018 Nov; 36(49):7472-7478. PubMed ID: 30420039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluations of rotavirus immunization for developing countries: a review of the literature.
    Tu HA; Woerdenbag HJ; Kane S; Rozenbaum MH; Li SC; Postma MJ
    Expert Rev Vaccines; 2011 Jul; 10(7):1037-51. PubMed ID: 21806398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence-based decision-making for vaccine introductions: Overview of the ProVac International Working Group's experience.
    Jauregui B; Garcia AG; Bess Janusz C; Blau J; Munier A; Atherly D; Mvundura M; Hajjeh R; Lopman B; Clark AD; Baxter L; Hutubessy R; de Quadros C; Andrus JK
    Vaccine; 2015 May; 33 Suppl 1(0 1):A28-33. PubMed ID: 25919170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient-Level Costing Data.
    Bar-Zeev N; Tate JE; Pecenka C; Chikafa J; Mvula H; Wachepa R; Mwansambo C; Mhango T; Chirwa G; Crampin AC; Parashar UD; Costello A; Heyderman RS; French N; Atherly D; Cunliffe NA;
    Clin Infect Dis; 2016 May; 62 Suppl 2(Suppl 2):S220-8. PubMed ID: 27059360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the Universal Immunization Programme and introduction of a rotavirus vaccine in India with IndiaSim.
    Megiddo I; Colson AR; Nandi A; Chatterjee S; Prinja S; Khera A; Laxminarayan R
    Vaccine; 2014 Aug; 32 Suppl 1():A151-61. PubMed ID: 25091670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiological and Economic Impact of Monovalent and Pentavalent Rotavirus Vaccines in Low and Middle Income Countries: A Cost-effectiveness Modeling Analysis.
    Paternina-Caicedo A; De la Hoz-Restrepo F; Alvis-Guzmán N
    Pediatr Infect Dis J; 2015 Jul; 34(7):e176-84. PubMed ID: 25923424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.